Harald Stein
哈拉尔德·斯坦因
MD
Professor Emeritus of Pathology病理学荣誉教授
👥Biography 个人简介
Harald Stein is a legendary European hematopathologist who pioneered immunohistochemical characterization of lymphomas using CD antigen panels. He contributed foundational work to the Kiel classification and subsequent WHO lymphoma classification, and is recognized for defining classical Hodgkin lymphoma markers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CD Marker Characterization in Lymphoma
Pioneered systematic immunohistochemical analysis using CD antigen panels to classify lymphoma subtypes, establishing methods now standard worldwide.
Kiel and WHO Classification Contributions
Co-developed the Kiel classification of lymphomas and contributed expertise to multiple editions of the WHO classification of lymphoid neoplasms.
Reed-Sternberg Cell Biology
Characterized immunophenotype of Reed-Sternberg cells and defined CD15/CD30 co-expression as a hallmark of classical Hodgkin lymphoma.
Representative Works 代表性著作
Immunohistochemical analysis of the organization of normal lymphoid tissue and non-Hodgkin lymphomas
Journal of Histochemistry and Cytochemistry (1982)
Established comprehensive IHC framework for lymphoma subclassification using B- and T-cell marker panels.
The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue
Blood (1985)
Defined CD30 (Ki-1) as a key diagnostic marker, enabling distinction of Hodgkin lymphoma and ALCL.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elaine Jaffe
National Cancer Institute, NIH
Nancy Lee Harris
Massachusetts General Hospital, Harvard Medical School
Philippe Gaulard
Henri Mondor Hospital, Paris Est University
Andreas Rosenwald
University of Würzburg
关注 哈拉尔德·斯坦因 的研究动态
Follow Harald Stein's research updates
留下邮箱，当我们发布与 Harald Stein（Charité – Universitätsmedizin Berlin）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment